insights_auto
Why is ALNY up 3,63%?
Dive Deeperchevron_right
ALNY:NASDAQ
Alnylam Pharmaceuticals, Inc.
232,68 $
arrow_upward
+3,63%(+8,15) 1D
9 қаз., 16:00:01 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNY...
Open
224,74 $
High
232,94 $
Low
222,70 $
Mkt. cap
31,13 млрд
Avg. vol.
1,50 млн
Volume
4,00
P/E ratio
39,60
52-wk high
495,55 $
52-wk low
197,81 $
EPS
5,88 $
Beta
0,28
Shares outstanding
133,81 млн
No. of employees
2 мың
Open
224,74 $
High
232,94 $
Low
222,70 $
Mkt. cap
31,13 млрд
Avg. vol.
1,50 млн
Volume
4,00
P/E ratio
39,60
52-wk high
495,55 $
52-wk low
197,81 $
EPS
5,88 $
Beta
0,28
Shares outstanding
133,81 млн
No. of employees
2 мың
News stories
From web sources and news partners
Investing.com
·
17 сағат бұрын
Alnylam EVP Bryan Supran sells $398,855 in shares
Investing.com Nigeria
·
17 сағат бұрын
Form 4 Alnylam Pharmaceuticals Inc For: 11 October By Investing.com
Simply Wall Street
·
19 сағат бұрын
How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors
Stock Traders Daily
·
1 күн бұрын
(ALNY) Price Dynamics and Execution-Aware Positioning
Profile
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
About Alnylam Pharmaceuticals, Inc.